Cosmo Pharmaceuticals NV (COPN.SW) stock: key figures, P/E, revenue and dividend
Health Care · Ireland · ISIN NL0011832936
Cosmo Pharmaceuticals NV financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 266.79 m EUR | 104.85 m EUR |
| Gross profit | 229.00 m EUR | 45.00 m EUR |
| Operating income | 148.28 m EUR | -6.94 m EUR |
| EBIT | 138.00 m EUR | -9.00 m EUR |
| Net income | 133.24 m EUR | -3.63 m EUR |
| Diluted EPS – continuing operations | 7.56 EUR | -0.21 EUR |
Full history since 2004, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Cosmo Pharmaceuticals NV
Cosmo N.V., a life sciences company, develops and manufactures pharmaceuticals and contracts for gastroenterology, dermatology, and health tech in Ireland and internationally. The company offers GI Genius, a computer-assisted system that uses artificial intelligence in real time to detect colorectal lesions; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Lialda/Mezavant/Mesavancol, a once-daily mesalamine tablet approved to help get active, mild to moderate ulcerative colitis into remission; Uceris/Cortiment, an oral tablet formulation that delivers budesonide directly to the lumen of the colon; Eleview, an injectable composition to allow endoscopists with excision of gastrointestinal lesions; Lumeblue, a diagnostic drug for the visualisation of colorectal lesions during colonoscopies; Aemcolo/Rifamycin, a pharmaceutical drug product in form of tablets that is approved for the treatment of travelers' diarrhoea; and Clascoterone, which is in phase-3 clinical trial for the treatment of male pattern hair loss. It is also developing novel UC treatment, which is in phase-2 clinical trial for the treatment of distal inflammatory bowel disease/distal ulcerative colitis/proctitis; BAD Treatment (CB-01-33), which is in phase-2 clinical trial for the treatment of colesevelam formulation/bile acid diarrhea; and CB-03-10, which is in phase-1 clinical trial for the treatment of oncology solid tumors, as well as provides Cosmo's AI technology, a GI Genius intelligent endoscopy system. The company was formerly known as Cosmo Pharmaceuticals N.V. and changed its name to Cosmo N.V. in April 2026. The company was founded in 1997 and is headquartered in Dublin, Ireland.
More stocks
- Accentro Real Estate AG (A4Y0.F)
- INKON Life Technology Co Ltd (300143.SZ)
- Avio SpA (AVIO.MI)
- Woori Technology Inc (032820.KQ)
- HORIZON BANCORP INC /IN/ (HBNC)
- Parade Technologies Ltd (4966.TWO)
- LX International Corp (001120.KS)
- NewPrinces SpA (NWL.MI)
- HighPeak Energy, Inc. (HPK)
- MYERS INDUSTRIES INC (MYE)
- Sunwave Communications Co Ltd (002115.SZ)
- Seneca Foods Corp (SENEB)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.